Rapid Therapeutic Science Laboratories, Inc. (RTSL)
Rapid Therapeutic Science Laboratories, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in De Leon, TX, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $883. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of -1.83 implies it has historically moved less than the broad market.
Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.
Rapid Therapeutic Science Laboratories, Inc. is most often compared with the following Healthcare names: